Study Finds Coelacanth Lacks 11 Jaw Muscles Previously Thought Present
A 2025 study published in Science Advances determined that the coelacanth, an ancient fish species, does not possess 11 jaw muscles that researchers had previously believed it had. The finding alters prior understanding of the fish's anatomy. The coelacanth is frequently referred to as a living fossil due to its evolutionary history.
discovermagazine.comA 2025 study reported that the coelacanth lacks 11 jaw muscles that researchers had previously thought the fish possessed. The coelacanth is an evolutionarily ancient fish species that has often been nicknamed a living fossil. The study findings indicate a need to revise earlier anatomical models of its jaw structure.
Background on the Coelacanth The species belongs to a lineage that dates back hundreds of millions of years. It was once believed to have gone extinct until living specimens were discovered in the 20th century. This rediscovery contributed to its status as a subject of significant scientific interest regarding evolutionary biology.
The research determined that the coelacanth is missing the 11 jaw muscles previously attributed to it. This adjustment in understanding its muscular anatomy may affect interpretations of how the fish feeds and how its jaw functions.
Key Facts
Potential Impact
- 01
Scientific models of coelacanth jaw anatomy will require revision.
- 02
Future research on the feeding mechanics of the coelacanth may change.
- 03
Understanding of evolutionary muscle development in fish could be affected.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…